Skip to main content
Erschienen in: Strahlentherapie und Onkologie 1/2016

01.01.2016 | Literatur kommentiert

Die stereotaktische Strahlentherapie unterstützt die Immunantwort

verfasst von: Prof. Dr. med. Dr. Esther G. C. Troost, M.D., Ph.D.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Auszug

Sharabi AB, Nirschi CJ, Kochel C et al (2015) Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune response via cross-presentation of tumor antigen. Cancer Immunol Res 3(4):345–355 …
Literatur
1.
Zurück zum Zitat Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16:630–637PubMedCrossRef Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16:630–637PubMedCrossRef
2.
Zurück zum Zitat De Ruysscher D, Wanders R, van Baardwijk A et al (2012) Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase ii trial (Nct01282450). J Thorac Oncol 7:1547–1555PubMedCrossRef De Ruysscher D, Wanders R, van Baardwijk A et al (2012) Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase ii trial (Nct01282450). J Thorac Oncol 7:1547–1555PubMedCrossRef
3.
Zurück zum Zitat Milano MT, Katz AW, Zhang H, Okunieff P (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83:878–886PubMedCrossRef Milano MT, Katz AW, Zhang H, Okunieff P (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83:878–886PubMedCrossRef
4.
Zurück zum Zitat Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373:123–135PubMedCrossRef Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373:123–135PubMedCrossRef
5.
Zurück zum Zitat Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723PubMedPubMedCentralCrossRef Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Rekers NH, Troost EG, Zegers CM, Germeraad WT, Dubois LJ, Lambin P (2014) Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives. Cancer Radiother 18:391–395PubMedCrossRef Rekers NH, Troost EG, Zegers CM, Germeraad WT, Dubois LJ, Lambin P (2014) Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives. Cancer Radiother 18:391–395PubMedCrossRef
7.
Zurück zum Zitat Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925–931PubMedPubMedCentralCrossRef Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925–931PubMedPubMedCentralCrossRef
8.
9.
Zurück zum Zitat Kroemer G, Zitvogel L (2012) Abscopal but desirable: the contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology 1:407–408PubMedPubMedCentralCrossRef Kroemer G, Zitvogel L (2012) Abscopal but desirable: the contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology 1:407–408PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Masucci GV, Wersall P, Kiessling R, Lundqvist A, Lewensohn R (2012) Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours. J Transl Med 10:104PubMedPubMedCentralCrossRef Masucci GV, Wersall P, Kiessling R, Lundqvist A, Lewensohn R (2012) Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours. J Transl Med 10:104PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I (2012) The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 85:293–295PubMedPubMedCentralCrossRef Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I (2012) The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 85:293–295PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Diamond J, Pilones K, Aryankalayil J, Vatner R, Formenti SC, Demaria S (2014) Radiotherapy induces responsiveness of a resistant mammary carcinoa to PD-1 blockade. J Immunother Cancer 2:159CrossRef Diamond J, Pilones K, Aryankalayil J, Vatner R, Formenti SC, Demaria S (2014) Radiotherapy induces responsiveness of a resistant mammary carcinoa to PD-1 blockade. J Immunother Cancer 2:159CrossRef
13.
Zurück zum Zitat Binder DC, Fu YX, Weichselbaum RR (2015) Radiotherapy and immune checkpoint blockade: potential interactions and future directions. Trends Mol Med 21:463–465PubMedCrossRef Binder DC, Fu YX, Weichselbaum RR (2015) Radiotherapy and immune checkpoint blockade: potential interactions and future directions. Trends Mol Med 21:463–465PubMedCrossRef
Metadaten
Titel
Die stereotaktische Strahlentherapie unterstützt die Immunantwort
verfasst von
Prof. Dr. med. Dr. Esther G. C. Troost, M.D., Ph.D.
Publikationsdatum
01.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 1/2016
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-015-0923-2

Weitere Artikel der Ausgabe 1/2016

Strahlentherapie und Onkologie 1/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.